Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients

Lamivudine, telbivudine, and entecavir are the first-line drugs covered by the Taiwan National Health Insurance as 3-year treatments for patients with chronic hepatitis B virus (HBV), but the optimal treatment duration of each remains unclear. We aimed to detect HBV treatment-cessation durability, a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ching-Chung Lin, Ming-Jong Bair, Chih-Jen Chen, Keng-Han Lee, Ming-Jen Chen, Chia-Yuan Liu, Chen-Wang Chang, Kuang-Chun Hu, Tai-Cherng Liou, Shee-Chan Lin, Horng-Yuan Wang, Cheng-Hsin Chu, Shou-Chuan Shih, Tsang-En Wang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2016-01-01
Edice:	Kaohsiung Journal of Medical Sciences
Témata:	Alanine aminotransferase Entecavir Hepatitis B virus Lamivudine Telbivudine
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1607551X15002582
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!